News

International Space Station National Lab Celebrates Milestone in Science

International Space Station National Lab Celebrates Milestone in Science

International Space Station National Lab Celebrates Scientific Milestone

Seventy-six peer-reviewed studies were published in the last fiscal year, the highest annual number so far, contributing to a total of nearly 630 overall. This record demonstrates the ISS National Lab's growing role in leveraging space-based research for scientific enrichment and commercial progress.

Impressive Results from Space-Based Research

The International Space Station (ISS) National Laboratory achieved remarkable success, showcasing the value of space-based investigations. The results span across diverse fields including biomedical research, advanced materials, Earth observation, and innovative technologies, all made possible by the unique conditions present in microgravity.

Record Number of Peer-Reviewed Publications

In the last fiscal year, an impressive total of 76 articles related to ISS National Lab-sponsored investigations were published, surpassing the previous high of 51. Fifteen of these publications appeared in prestigious scientific journals, signifying their critical relevance to national and global scientific priorities. The cumulative tally now stands at almost 630 peer-reviewed publications linked to ISS National Lab's initiatives.

Achievements in Research and Development

The ISS National Lab's achievements this year also included numerous patents and research-driven products, affirming its role as a driving force for high-impact research and technology advancements in low Earth orbit (LEO). Many groundbreaking findings from this past year were highlighted in Upward, the official magazine of the ISS National Lab, which details the impact of research this lab supports.

Notable Scientific Discoveries from the ISS

Several significant findings have emerged through ISS National Lab-affiliated experiments. Some standout achievements include:

  • ISS research guiding the development of an injectable cancer therapy by Merck & Co, leveraging microgravity to create uniform protein crystals and facilitating improved drug formulations.
  • Encapsulate's successful use of microgravity to cultivate three-dimensional tumors that resemble human cancers, paving the way for personalized cancer research.
  • MicroQuin's discovery of how microgravity affects cancer cell signaling, enabling the creation of a targeted small molecule therapeutic that spares healthy cells.
  • Oculogenex's research on age-related macular degeneration, finding promising prevention and treatment outcomes in microgravity environments.
  • Innovative advancements by Orbit Fab in in-space refueling technologies, successfully delivering hydrazine fuel to satellites and securing contracts to support U.S. Space Force operations.
  • New insights from the Alpha Magnetic Spectrometer team regarding the origins of lithium in cosmic rays, reshaping existing theories on elemental formation in the universe.
  • The continued success of the Genes in Space™ program, motivating students to engage with genetics experiments designed for space-based settings, which reinforces future workforce skills.

Looking Toward the Future

As remarks from ISS National Lab Chief Scientific Officer Michael Roberts note, the past year has significantly advanced scientific understanding and spurred innovations to tackle real-world challenges in various sectors including healthcare and technology development. As the ISS National Lab looks ahead, there is enthusiasm for building on this momentum, continuing to utilize the extraordinary environment of space to drive research that influences both life on Earth and the economy in LEO.

About the ISS National Laboratory

The International Space Station (ISS) serves as an unprecedented laboratory that allows for experiments and technology advancements that cannot be realized on Earth. The ISS National Laboratory is managed by the Center for the Advancement of Science in Space (CASIS), facilitating access to the microgravity environment for a broad array of research initiatives from various sectors.

The ISS National Lab actively supports scientific endeavors, government facilities, academic institutions, and the private industry, fostering space-based education and innovation to improve quality of life on Earth. For detailed insights and updates, subscribe to Upward.

Frequently Asked Questions

What is the ISS National Laboratory?

The ISS National Laboratory is a unique research facility located in low Earth orbit, which enables groundbreaking scientific research and technologies not possible on Earth.

How many peer-reviewed articles were published last year?

A record 76 peer-reviewed articles were published related to ISS National Lab-sponsored research, which is an increase from earlier years.

What types of research does the ISS National Lab support?

The ISS National Lab supports research in various fields, including biomedical research, materials science, Earth observation, and advanced technology development.

Who manages the ISS National Laboratory?

The ISS National Laboratory is managed by the Center for the Advancement of Science in Space (CASIS), which works under agreement with NASA.

How does research in microgravity benefit science?

Research conducted in microgravity allows scientists to observe and experiment under unique conditions that can lead to advancements in healthcare, technology, and other scientific fields.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 0

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Ruth, Mickey, Superman: Morphy's Auction Smorgasbord

Updated Category News Views 4

A Surreal Gathering of Icons and Memorabilia Who'd have thought you could snag both Babe Ruth and Mickey Mouse in one fell swoop? Well, come November 10-12, 2026, fans and collectors alike will have the opportunity at Morphy Auctions in Denver, PA. It's a dizzying array of Americana where cultural legend meets sports royalty, and we're not talking pocket change here. Babe...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 24

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
Roadrunner's Bold Move: New LTL Service and Rate Hike

Updated Category News Views 3

When you shake up the status quo in logistics, you better be ready for the ride. Roadrunner Freight is doing just that with the launch of its first-ever outbound Canada-to-U.S. LTL service. They're shaking up a market that's been bogged down with inefficiencies for far too long. This isn't just another lane to add to a map; it's a new passage for Canadian goods, paving a...

Continue Reading
Invisors Expands PayBill Suite for Staffing Efficiency

Updated Category News Views 4

Invisors Doubles Down on Workday Integration The winds of change are whispering in the Professional & Business Services sector as Invisors rolls out its enhanced PayBill Suite. This move isn't just another tick on some corporate checklist; it's a serious play to streamline the gnarly process of transitions that staffing firms face. Invisors is tying this suite tightly...

Continue Reading
FP Movement Opens Energizing Boutique in Cranston, RI

Updated Category News Views 23

FP Movement Expands with Style in Rhode Island FP Movement is shaking things up in Cranston, Rhode Island, bringing its signature activewear vibe to Garden City Center with a new shop. It’s not just about buying leggings anymore; it’s about diving into a lifestyle that screams energy and community spirit. The store, which spans 1,209 selling-square-feet, opened its...

Continue Reading
FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

Updated Category News Views 23

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Continue Reading
JJ Lin's Iconic Singapore Grand Prix Show With 20 Songs

Updated Category News Views 3

Nothing beats the thrill of a live performance under a night sky, with the adrenaline of a Formula 1 race still in the air. On October 9, 2026, Mandopop superstar JJ Lin captivated the crowd at the Padang Stage of the Singapore Grand Prix, delivering not just a concert but a spectacle of international scale. Stage Spectacle with Precision JJ Lin took control like a...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 26

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
ASPR AI Unveils Private Sales Agent Studio

Updated Category News Views 11

Pushing Sales AI Into a Secure Future Picture a world where your most sensitive sales data stays safely behind your own digital doors. ASPR AI is shaking up the game by launching its Private Sales Agent Studio, a move that catapults enterprise sales management into a new era of control and customization. Why Private Means Business Here's the meat of it: sales AI usually...

Continue Reading

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 78

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
Understanding Recent Trends in Canadian Stocks and Markets

Updated Category News Views 329

Canadian Stock Market Overview Recently, the Canadian stock market experienced a decline, reflecting a challenging trading environment. The decline was multifaceted, with notable tumbles in sectors such as the Consumer Staples, REITs, and Healthcare, which significantly influenced overall market performance. Investors and analysts are keenly observing these fluctuations,...

Continue Reading
Discover Key Trends in Network Observability for IT Success

Updated Category News Views 137

Emerging Trends in Network Observability Join experts as they discuss how IT leaders can adapt observability tools to meet modern network challenges. Enterprise Management Associates (EMA) is hosting an insightful webinar titled "Your NetOps Tools Are Aging Faster Than Your Network: 5 Emerging Trends That Are Reshaping Network Observability." Shamus McGillicuddy, Vice...

Continue Reading
Realbotix Secures Payment in Genesis Restructuring Efforts

Updated Category News Views 74

Realbotix Achieves Major Financial Recovery Realbotix Corp. (TSX-V: XBOT | Frankfurt Stock Exchange: 76M0.F | OTC: XBOTF) is making waves in the news by recently securing a significant cash payment of US$743,500 as part of its ongoing restructuring efforts with Genesis Global Capital. This milestone is a positive step for the Company as it works through the challenges of...

Continue Reading
Immedica Pharma's Loargys: Pioneering Hope in Rare Disease

Updated Category News Views 210

Game-Changing Approval or Just Another Hype Train? Time for a gut check: Immedica Pharma just made waves with its Loargys® (pegzilarginase-nbln), snagging accelerated FDA approval for treating hyperargininemia tied to Arginase 1 Deficiency (ARG1-D). So what's the big deal? Well, basically, we're talking about a breakthrough here—it's the first therapy proven to lower...

Continue Reading